Enzyme injection could loosen stiff joints in brain and spinal cord injuries

NCT ID NCT07693556

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This trial tests whether injecting collagenase—an enzyme that breaks down tough connective tissue—can reduce contracture (stiff, shortened muscles) and spasticity (uncontrolled muscle tightness) in people with neurological impairments like stroke, brain injury, or spinal cord injury. The study enrolls 15 adults who are at least 6 months post-injury and have tendon contracture. Researchers will measure changes in muscle tone and joint movement, while closely watching for side effects such as tendon damage or injection-site reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
XIAFLEX (collagenase) injection
What this could lead to
If it works, this could offer a new, non-surgical option to reduce muscle tightness and improve joint movement in people with neurological conditions.
What could go wrong
This is a very early, small trial (15 people). Risks include tendon rupture, ligament damage, skin tears, and injection-site pain or swelling. It may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥ 6 months post stroke, brain injury or spinal cord injury, medically stable; * clinical diagnosis of tendon contracture Exclusion Criteria: * Is hypersensitive to XIAFLEX or collagenase; * Is currently adjusting tone alternating medications (e.g., baclofen), or * Received botulinum toxin injection to target areas \<4 months, or phenol injections \< 9 months; * Received surgical release of tendons; * Is a pregnant woman; * Has coagulation disorders, including those who receive concomitant anticoagulants (except for low-dose aspirin). * has heritable connective tissue disorders, including those within the Ehlers-Danlos syndrome (EDS) spectrum.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contracture are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Contracture

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The University of Texas Health Science Center at Houston

    Houston, Texas, 77030, United States